Prevalence of hepatitis C virus infection among prisoners in Iran: a systematic review and meta-analysis

被引:32
作者
Behzadifar, Masoud [1 ]
Gorji, Hasan Abolghasem [2 ]
Rezapour, Aziz [2 ]
Bragazzi, Nicola Luigi [3 ]
机构
[1] Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Dept Hlth Serv Management, Tehran, Iran
[2] Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, Iran
[3] Univ Genoa, Sch Publ Hlth, Dept Hlth Sci DISSAL, Genoa, Italy
关键词
Hepatitis C virus; Prevalence; Prisoners; Iran; Meta-analysis; Systematic review; INJECTION-DRUG USE; VIRAL-HEPATITIS; HARM REDUCTION; GLOBAL BURDEN; RISK-FACTORS; HIV; INMATES; COHORT; HCV; EPIDEMIOLOGY;
D O I
10.1186/s12954-018-0231-0
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Hepatitis C virus (HCV) is one of the major public health problems both in developed and developing countries. Prison represents a high-risk environment for prisoners, in that it is characterized by high-risk behaviors such as injecting drug use (IDU), tattooing, unprotected sexual intercourses, or sharing syringes. The aim of this study was to quantitatively evaluate the prevalence of HCV among Iranian prisoners conducting a systematic review and meta-analysis. Methods: We searched different scholarly databases including Embase, PubMed/MEDLINE, ISI/Web of Sciences, the Cochrane library, Scopus, CINAHL, and PsycINFO as well as Iranian bibliographic thesauri (namely, Barakatns, MagIran, and SID) up to December 2017. The Newcastle Ottawa Scale (NOS) was used to assess the quality of the studies included. HCV prevalence rate with its 95% confidence interval (CI) was estimated using the DerSimonian-Laird random-effects model, with Freeman-Tukey double arcsine transformation. Egger's regression test was used to evaluate publication bias. Results: Finally, 17 articles were selected based on inclusion and exclusion criteria. Overall, 18,693 prisoners were tested. Based on the random-effects model, the prevalence of HCV among Iranian prisoners was 28% (CI 95% 21-36) with heterogeneity of I-2 = 99.3% (p = 0.00). All studies used an ELISA test for the evaluation of HCV antibodies. The findings of this study showed that the highest prevalence rate (53%) was among prisoners who inject drugs. Conclusion: The findings of our study showed that the prevalence of HCV among Iranian prisoners is dramatically high. Managing this issue in Iran's prisons requires careful attention to the availability of health facilities and instruments, such as screening, and harm reduction policies, such as giving sterile syringes and needles to prisoners. An integrated program of training for prisoners, prison personnel and medical staff is also needed to improve the level of health condition in prisons.
引用
收藏
页数:9
相关论文
共 48 条
  • [1] Alavian S. M., 2009, Iranian Journal of Clinical Infectious Diseases, V4, P47
  • [2] Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey
    Allwright, S
    Bradley, F
    Long, J
    Barry, J
    Thornton, L
    Parry, JV
    [J]. BRITISH MEDICAL JOURNAL, 2000, 321 (7253) : 78 - 82
  • [3] Prevalence and correlates of hepatitis C virus infection among inmates at two New York State correctional facilities
    Alvarez, Kimberly J.
    Befus, Montina
    Herzig, Carolyn T. A.
    Larson, Elaine
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2014, 7 (06) : 517 - 521
  • [4] [Anonymous], 2017, HEPAT MON, DOI DOI 10.5812/hepatmon.14308
  • [5] [Anonymous], 2013, EURO SURVEILL, DOI DOI 10.2807/1560-7917.ES2013.18.28.20524
  • [6] [Anonymous], HEP C FACT SHEET 201
  • [7] [Anonymous], MMWR RECOMM REP
  • [8] Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting
    Brandolini, Micaela
    Novati, Stefano
    De Silvestri, Annalisa
    Tinelli, Carmine
    Patruno, Savino Francesco Antonio
    Ranieri, Roberto
    Seminari, Elena
    [J]. BMC PUBLIC HEALTH, 2013, 13
  • [9] Prisoners are at risk for hepatitis C transmission
    Butler, T
    Kariminia, A
    Levy, M
    Kaldor, J
    [J]. EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2004, 19 (12) : 1119 - 1122
  • [10] Meta-analysis in clinical trials revisited
    DerSimonian, Rebecca
    Laird, Nan
    [J]. CONTEMPORARY CLINICAL TRIALS, 2015, 45 : 139 - 145